Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas
To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.
Lymphomas
disease free survival, 5 years
Autologous CIK transfusion within 3 days post CD20 antibody treatment.